{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T19:29:27Z","timestamp":1775935767284,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bmcl.2025.130114","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:20:53Z","timestamp":1738023653000},"page":"130114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Synthesis and evaluation of KX-01 analogs with an exploration of linker attachment points for antibody-drug conjugates"],"prefix":"10.1016","volume":"120","author":[{"given":"Yeju","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da Eun","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaebeom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byumseok","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-5118","authenticated-orcid":false,"given":"Hongjun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130114_b0005","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41580-021-00399-x","article-title":"Regulation of microtubule dynamics, mechanics and function through the growing tip","volume":"22","author":"Gudimchuk","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130114_b0010","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022608","article-title":"Microtubules and Microtubule-Associated Proteins","volume":"10","author":"Goodson","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.bmcl.2025.130114_b0015","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.3390\/cancers13225650","article-title":"Microtubule targeting agents in disease: classic drugs, novel roles","volume":"13","author":"Wordeman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmcl.2025.130114_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130114_b0025","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.tcb.2018.05.001","article-title":"Microtubule-targeting agents: strategies to hijack the cytoskeleton","volume":"28","author":"Steinmetz","year":"2018","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130114_b0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1535-7163.MCT-13-0791","article-title":"Targeting microtubules by natural agents for cancer therapy","volume":"13","author":"Mukhtar","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2025.130114_b0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody\u2013drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130114_b0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2025.130114_b0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2025.130114_b0050","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2025.130114_b0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody\u2013drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmcl.2025.130114_b0060","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2025.130114_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmcl.2025.130114_b0070","doi-asserted-by":"crossref","first-page":"T58","DOI":"10.1016\/j.ad.2021.07.016","article-title":"[Translated article] Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis","volume":"113","author":"Gilaberte","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.bmcl.2025.130114_b0075","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acs.jmedchem.8b00164","article-title":"Discovery of novel dual mechanism of action src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361)","volume":"61","author":"Smolinski","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0080","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-011-1513-3","article-title":"KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor \u03b1 positive breast cancer","volume":"132","author":"Anbalagan","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.bmcl.2025.130114_b0085","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1158\/1535-7163.MCT-12-0146","article-title":"Peptidomimetic Src\/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER\/PR\/HER2-negative tumor xenografts","volume":"11","author":"Anbalagan","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2025.130114_b0090","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130114_b0095","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1016\/j.ejmech.2011.07.050","article-title":"Thiazolyl N-benzyl-substituted acetamide derivatives: Synthesis, Src kinase inhibitory and anticancer activities","volume":"46","author":"Fallah-Tafti","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0100","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1021\/acs.jmedchem.0c01961","article-title":"Design, synthesis, and bioactivity evaluation of dual-target inhibitors of tubulin and Src kinase guided by crystal structure","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0105","doi-asserted-by":"crossref","first-page":"35583","DOI":"10.1039\/D3RA06790D","article-title":"Synthesis and evaluation of tirbanibulin derivatives: a detailed exploration of the structure\u2013activity relationship for anticancer activity","volume":"13","author":"Park","year":"2023","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmcl.2025.130114_b0110","doi-asserted-by":"crossref","first-page":"18099","DOI":"10.1074\/jbc.RA119.010732","article-title":"Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of \u03b2-tubulin explains KXO1\u2019s low clinical toxicity","volume":"294","author":"Niu","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0115","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an assurance for controlled delivery of antibody-drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmcl.2025.130114_b0120","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody\u2013drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmcl.2025.130114_b0125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tips.2011.11.002","article-title":"Targeting Src family kinases in anti-cancer therapies: turning promise into triumph","volume":"33","author":"Zhang","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmcl.2025.130114_b0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","article-title":"Src kinases as therapeutic targets for cancer","volume":"6","author":"Kim","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2025.130114_b0135","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmcl.2025.130114_b0140","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3390\/pharmaceutics14081564","article-title":"An overview on immunogenic cell death in cancer biology and therapy","volume":"14","author":"Rodrigues","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmcl.2025.130114_b0145","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmcl.2025.130114_b0150","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1565859","article-title":"Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells","volume":"8","author":"Bauzon","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bmcl.2025.130114_b0155","first-page":"221","article-title":"Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity","volume":"7","author":"Wang","year":"2024","journal-title":"Antib Ther"},{"key":"10.1016\/j.bmcl.2025.130114_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216167","article-title":"Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers","volume":"562","author":"Shi","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmcl.2025.130114_b0165","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/kjm2.12375","article-title":"Mechanisms of immunogenic cell death and immune checkpoint blockade therapy","volume":"37","author":"Lin","year":"2021","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.bmcl.2025.130114_b0170","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jacsau.2c00448","article-title":"40 years of duocarmycins: a graphical structure\/function review of their chemical evolution, from SAR to prodrugs and ADCs","volume":"2","author":"Felber","year":"2022","journal-title":"JACS Au"},{"key":"10.1016\/j.bmcl.2025.130114_b0175","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","article-title":"Duocarmycin-based antibody\u2013drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress","volume":"26","author":"Yao","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmcl.2025.130114_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122886","article-title":"Recent advances in SN-38 drug delivery system","volume":"637","author":"Yang","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bmcl.2025.130114_b0185","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1080\/10717544.2021.2008053","article-title":"Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates","volume":"28","author":"Liu","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.bmcl.2025.130114_b0190","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1021\/acs.bioconjchem.7b00576","article-title":"Immolation of p-aminobenzyl ether linker and payload potency and stability determine the cell-killing activity of antibody\u2013drug conjugates with phenol-containing payloads","volume":"29","author":"Zhang","year":"2018","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126782","article-title":"Design, synthesis and biological evaluation of phenol-linked uncialamycin antibody-drug conjugates","volume":"30","author":"Poudel","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130114_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113355","article-title":"Combretastatin A4-derived payloads for antibody-drug conjugates","volume":"216","author":"Huang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0205","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1021\/acs.bioconjchem.9b00340","article-title":"Aryl sulfate is a useful motif for conjugating and releasing phenolic molecules: sulfur fluorine exchange click chemistry enables discovery of ortho-hydroxy-protected aryl sulfate linker","volume":"30","author":"Park","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0210","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1021\/acs.bioconjchem.0c00116","article-title":"Sulfonate version of OHPAS linker has two distinct pathways of breakdown: elimination route allows para-hydroxy-protected benzylsulfonate (PHP-BS) to serve as an alternative self-immolative group","volume":"31","author":"Park","year":"2020","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0215","doi-asserted-by":"crossref","first-page":"11958","DOI":"10.1021\/acs.jmedchem.1c00541","article-title":"Development of novel glucocorticoids for use in antibody\u2013drug conjugates for the treatment of inflammatory diseases","volume":"64","author":"Han","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0220","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejmech.2018.10.024","article-title":"Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents","volume":"161","author":"Almaliti","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0225","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.bmcl.2025.130114_b0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1021\/jm00137a001","article-title":"A novel connector linkage applicable in prodrug design","volume":"24","author":"Carl","year":"1981","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130114_b0235","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2500023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2500023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T09:04:50Z","timestamp":1741511090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2500023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":47,"alternative-id":["S0960894X2500023X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130114","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of KX-01 analogs with an exploration of linker attachment points for antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130114"}}